Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC.
Status:
Not yet recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multicenter, exploratory Phase II study sponsored by
Astrazeneca Investment (China) Co., LTD. to evaluate the efficacy and safety of Osimertinib
with Platinum plus Pemetrexed Chemotherapy, as First-line Treatment in Recurrent or Locally
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients with Uncommon Epidermal
Growth Factor Receptor Mutations (EGFRm).